De-risk your clinical trials in all kinds of hereditary diseases
What if you could select the right participants for your hereditary diseases trials?
Whether you are running clinical trials in Parkinson’s disease, Alzheimer’s disease, cardiovascular disease or other hereditary diseases, you can reduce the risk of trial failure by identifying potential trial participants based on genotypic and phenotypic criteria.
Capitalize on our global partnership with Helix and sequence the DNA of every participant in your clinical trial using an exome assay developed by Helix.
Helix was the first laboratory to have an exome assay authorized by the FDA.
Call us during our office hours (Monday to Friday): 800-426-8157
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user operator manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).
This advertisement was sent by QIAGEN. If this email was forwarded to you and you‘d like to receive future communications and advertisements, please sign up here.
